CJC-1295 (with DAC) Product Brief

Ready-to-Sell Research Product Sheet

1. Compound Overview

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone releasing hormone (GHRH).
The DAC modification significantly extends the half-life of the peptide, allowing for prolonged stimulation of growth hormone release.

CJC-1295 with DAC is commonly studied in research exploring growth hormone signaling, metabolic regulation, recovery pathways, and body composition.

2. Mechanism of Interest

CJC-1295 with DAC is studied for several biological mechanisms:

• Activation of the GHRH receptor
  • Prolonged stimulation of endogenous growth hormone release
  • Increased circulating growth hormone levels due to extended half-life
  • Potential elevation of IGF‑1 signaling pathways
  • Influence on metabolic and recovery-related pathways

3. Research Areas Being Explored

• Growth hormone regulation research
  • Body composition studies
  • Recovery and regeneration pathways
  • Metabolic signaling studies
  • Endocrine system research

4. Suggested Research Vial Sizes

• 2 mg lyophilized vial
  • 5 mg lyophilized vial
  • 10 mg research vial

5. Example Reconstitution Chart

Example mixing protocols commonly used in research contexts:

2 mg vial + 1 mL bacteriostatic water = 2 mg/mL concentration

5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL concentration

10 mg vial + 2 mL bacteriostatic water = 5 mg/mL concentration

These concentrations allow accurate measurement using insulin syringes for laboratory research settings.

6. Label Information for Vials

• Compound name: CJC-1295 (with DAC)
  • Total amount per vial (mg)
  • Lot / batch number
  • Manufacturing date
  • Storage instructions (2–8°C recommended)
  • Research use only disclaimer

7. Market Positioning

CJC-1295 with DAC is commonly positioned in the growth hormone research peptide category.

It is frequently marketed for research involving:

• Long-acting growth hormone stimulation models
  • Body composition research
  • Recovery and regenerative studies
  • Metabolic and endocrine signaling pathways

8. Example Research Stack Categories

• CJC-1295 (with DAC) + Ipamorelin
  • CJC-1295 (with DAC) + BPC-157
  • CJC-1295 (with DAC) + TB-500
  • CJC-1295 (with DAC) + IGF‑1 related research peptides

9. Safety and Regulatory Notes

CJC-1295 with DAC is not approved by the FDA for medical treatment and is commonly distributed as a research compound.

This document is intended for informational and research product description purposes only.